Rejuvenate Bio
PrivateLast Round
Crowdfunding
Oct 19, 2026
Est. Valuation
$69.18M
Total Funding Raised
$17.5M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Rejuvenate Bio is a biotechnology company that develops gene therapies to treat chronic, age-related diseases in humans and animals.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Rejuvenate Bio Comparables
Compare Rejuvenate Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genflow Biosciences | 84% | |
| Turn Biotechnologies | 80% | |
| Life Biosciences | 79% |
Rejuvenate Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Crowdfunding | Oct 19, 2026 | ||||
| Financing | Jun 8, 2026 | ||||
| Grant | Jul 1, 2024 | ||||
| Series A | Apr 16, 2021 |
Rejuvenate Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kendall Capital Partners | Financing, Crowdfunding, Series A |
| Connecticut Innovations | Financing |
| Digitalis Ventures | Financing, Crowdfunding, Series A |
| California Institute for Regenerative Medicine | Grant |
| KdT Ventures | Crowdfunding, Series A |
| VCapital | Crowdfunding, Series A, Financing |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 19, 2026
Raised funds through Wefunder platform.
- Aug 28, 2026
Grew 20% QoQ, from 15 to 18 employees.
Recent news
Latest coverage and updates
- is_developingOct 27, 2026
Rejuvenate Bio, Inc. is developing a gene therapy to treat mitral valve disease in companion dogs and plans to eventually apply it to metabolic diseases and lifespan extension.
- is_developingOct 19, 2026
Rejuvenate Bio, Inc. is developing a gene therapy that works in dogs and is being extended for potential use in people, with reported preclinical results including cardiac repair and improved metabolic health.
- receives_financingOct 19, 2026
In Oct '26, Rejuvenate Bio, Inc. raises more than $3.2M under the Reg CF exemption on Wefunder, with the round scheduled to close that month and a concurrent round matching the offering after raising over $6M.
Rejuvenate Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Rejuvenate Bio's valuation, stock price, and market status.
Is Rejuvenate Bio a public or private company?
Rejuvenate Bio is a private company.
What is the current stock price of Rejuvenate Bio?
Rejuvenate Bio is a private company, so its shares have no public market price. Caplight tracks Rejuvenate Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Rejuvenate Bio worth (valuation)?
Rejuvenate Bio's valuation is estimated at $69.2M based on funding round data.
Can I buy Rejuvenate Bio stock?
Rejuvenate Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Rejuvenate Bio's last funding round?
Rejuvenate Bio's most recent funding round was Crowdfunding on October 19, 2026.
Who are the main investors in Rejuvenate Bio?
Key investors in Rejuvenate Bio include Kendall Capital Partners, VCapital.
Will Rejuvenate Bio IPO soon?
No public IPO plans have been announced for Rejuvenate Bio.
How can I track Rejuvenate Bio secondary market activity?
Caplight tracks bids, offers, and trades in Rejuvenate Bio's shares on secondary markets.